Legal status · United States
Is Erythropoietin legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
Yes. Erythropoietin is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Erythropoietin in the United States at a glance
| Classification | FDA-approved, prescription only |
|---|---|
| Note | Approved for anaemia of chronic kidney disease and certain chemotherapy-related anaemias, with a boxed warning stating that no haemoglobin target, dose or dosing strategy has been identified that avoids the increased risks of death, myocardial infarction, stroke, thromboembolism and tumour progression. Prohibited in sport. |
| FDA approval status | FDA approved since 1989 for anaemia, with boxed warnings. Verified on 11 September 2026: EPOGEN and PROCRIT (epoetin alfa, BLA 103234) approved 1 June 1989; ARANESP (darbepoetin alfa, BLA 103951) approved 17 September 2001; MIRCERA (BLA 125164) approved 14 November 2007; RETACRIT (BLA 125545) approved 15 May 2018. All listed Prescription. The boxed warning covers increased death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis and tumour progression or recurrence. |
| Human studies cited | 4 of 7 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Erythropoietin profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
FDA has approved Erythropoietin for at least one labeled indication, so a pharmaceutical-grade product exists in the United States and is dispensed on prescription.
- 02
Approval is indication-specific. Uses outside the label are a clinical decision for a prescriber, not something the approval itself authorizes.
- 03
Unlicensed online vials, including those labeled "research use only", are not the approved product and are not covered by the approval.
What Erythropoietin is
The kidney hormone that drives red cell production, approved since 1989 for anaemia. Three randomised trials that pushed haemoglobin toward normal found harm rather than benefit, including a doubling of stroke in 4,038 people, and every product now carries a boxed warning.
Erythropoietin is a 166 amino acid glycoprotein hormone made mainly by cells in the kidney in response to low oxygen. It tells bone marrow progenitors to survive and multiply into red blood cells.
Mechanism: In humans, erythropoietin binds the EPO receptor on erythroid progenitor cells, signalling through JAK2 and STAT5 to prevent apoptosis and drive proliferation, which raises red cell mass over days to weeks. The same signalling raises blood viscosity and platelet reactivity, which is the accepted explanation for the thrombotic and stroke risk seen in the normalisation trials.
Regulatory history: FDA approved since 1989 for anaemia, with boxed warnings. Verified on 11 September 2026: EPOGEN and PROCRIT (epoetin alfa, BLA 103234) approved 1 June 1989; ARANESP (darbepoetin alfa, BLA 103951) approved 17 September 2001; MIRCERA (BLA 125164) approved 14 November 2007; RETACRIT (BLA 125545) approved 15 May 2018. All listed Prescription. The boxed warning covers increased death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis and tumour progression or recurrence.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Erythropoietin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Erythropoietin in other countries
Frequently asked questions
Is Erythropoietin legal in the United States?
Yes. Erythropoietin is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 4 human studies are cited on its profile. Note: Approved for anaemia of chronic kidney disease and certain chemotherapy-related anaemias, with a boxed warning stating that no haemoglobin target, dose or dosing strategy has been identified that avoids the increased risks of death, myocardial infarction, stroke, thromboembolism and tumour progression. Prohibited in sport.
Can I buy Erythropoietin in the United States?
Only with a prescription. Erythropoietin is classified as "FDA-approved, prescription only" in the United States, so it is dispensed by pharmacies against a prescription for its approved indication. Buying it from unlicensed online sellers or as a "research chemical" is outside that system and carries no regulatory protection. Note: Approved for anaemia of chronic kidney disease and certain chemotherapy-related anaemias, with a boxed warning stating that no haemoglobin target, dose or dosing strategy has been identified that avoids the increased risks of death, myocardial infarction, stroke, thromboembolism and tumour progression. Prohibited in sport.
Is Erythropoietin FDA approved?
Yes. FDA status: FDA approved since 1989 for anaemia, with boxed warnings. Verified on 11 September 2026: EPOGEN and PROCRIT (epoetin alfa, BLA 103234) approved 1 June 1989; ARANESP (darbepoetin alfa, BLA 103951) approved 17 September 2001; MIRCERA (BLA 125164) approved 14 November 2007; RETACRIT (BLA 125545) approved 15 May 2018. All listed Prescription. The boxed warning covers increased death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis and tumour progression or recurrence.. Current US classification: "FDA-approved, prescription only". On the evidence, 4 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Erythropoietin live on its compound profile.
Erythropoietin profileThis page is general information about the regulatory status of Erythropoietin in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.